HCA Florida Northwest Hospital Acquires Anovo Surgical System

HCA Florida Northwest Hospital has acquired the Anovo™ Surgical System for use in transvaginal benign gynecological procedures including hysterectomies. The Anovo System is the first and only FDA-authorized surgical robot with features including shoulder, elbow, and wrist joints designed to mimic human arms and provide human level dexterity.

“It is essential for surgeons to use the most advanced tools and technologies to ensure we deliver optimal care to our patients, and this system presents several advantages compared to other available robotic technologies,” said Daniel Gomez, MD, FACOG, FACS, a minimally invasive gynecologic surgeon and assistant program director of the OBGYN Residency Program at HCA Florida Northwest Hospital. “By enabling the transvaginal approach to benign gynecological procedures including benign hysterectomies, we can perform minimally invasive surgery that may deliver benefits including less pain after surgery, leading to a faster recovery, and virtually no visible scarring. We are also excited to train the next generation of gynecologic surgeons on this new platform to further advance the surgical care that our current OBGYN residents will provide to their patients in the future.”

The Anovo Surgical System was granted de novo marketing authorization from the U.S. Food and Drug Administration (FDA) in February 2021 for use in single site, natural orifice laparoscopic-assisted transvaginal benign surgical procedures including benign hysterectomy, salpingectomy, oophorectomy, adnexectomy, and ovarian cyst removal. Multiple instruments can be introduced to the body through a single portal and the unprecedented articulation offers optimal access and working angles.

Anovo Surgical System is designed to enable surgeons to use the transvaginal approach in gynecological procedures, which has been well documented in clinical research as providing benefits including less patient pain and scarring, shorter recovery times and reduced infection rates, compared to other approaches.[i] In addition, the Anovo System requires a much smaller footprint and costs significantly less than conventional robotic systems, making it possible for more hospitals and ambulatory surgery centers to acquire the system and offer more patients the benefits of less invasive robotic surgery.

“We are pleased to have growing support from leading medical facilities in Florida including HCA Florida Northwest Hospital and hope to continue our momentum as we work to build broader commercial adoption of the Anovo System,” said Dvir Cohen, CEO and Co-Founder of Momentis. “We are dedicated to making this innovative technology available to more women and improving their surgical experience as well as that of the surgeons.”

[i] Aarts JWM, Nieboer TE, Johnson N, Tavender E, Garry R, Mol BWJ, Kluivers KB. Surgical approach to hysterectomy for benign gynaecological disease. Cochrane Database Syst Rev. 2015. 2015 Aug 12;2015(8):CD003677. doi: 10.1002/14651858.CD003677.pub5.

 

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”